Circadian Dysfunction and Melatonin Alterations in Progressive Supranuclear Palsy

Circadian Dysfunction and Melatonin Alterations in Progressive Supranuclear Palsy

Overview

Circadian rhythm disruption is a prevalent and underrecognized feature of progressive supranuclear palsy (PSP), contributing to sleep-wake cycle disturbances, cognitive decline, and overall disease progression. The suprachiasmatic nucleus (SCN) and its downstream melatonin signaling pathways represent key sites of vulnerability in PSP pathophysiology.

The circadian system in mammals comprises:

• Suprachiasmatic nucleus (SCN) — master circadian clock in the hypothalamus
• Melatonin synthesis — primarily from the pineal gland, regulated by SCN
• Peripheral clocks — present in most organs and tissues
• Entraining cues — light, feeding, temperature, and melatonin

In PSP, tau pathology invades the SCN and related hypothalamic structures, disrupting circadian timekeeping. Additionally, pineal gland dysfunction reduces melatonin output, further compromising circadian alignment.

Pathophysiology

SCN Tau Pathology

The suprachiasmatic nucleus is particularly vulnerable to tau pathology in PSP:

| Finding | Evidence |
|---------|----------|
| SCN neuronal loss | Postmortem studies show 30-50% neuronal loss in PSP |
| Tau inclusion formation | 4R-tau inclusions documented in SCN neurons |
| Neuroinflammation | Activated microglia surrounding SCN |
| Functional disconnection | Loss of SCN output to peripheral clocks |

...

Circadian Dysfunction and Melatonin Alterations in Progressive Supranuclear Palsy

Overview

Circadian rhythm disruption is a prevalent and underrecognized feature of progressive supranuclear palsy (PSP), contributing to sleep-wake cycle disturbances, cognitive decline, and overall disease progression. The suprachiasmatic nucleus (SCN) and its downstream melatonin signaling pathways represent key sites of vulnerability in PSP pathophysiology.

The circadian system in mammals comprises:

• Suprachiasmatic nucleus (SCN) — master circadian clock in the hypothalamus
• Melatonin synthesis — primarily from the pineal gland, regulated by SCN
• Peripheral clocks — present in most organs and tissues
• Entraining cues — light, feeding, temperature, and melatonin

In PSP, tau pathology invades the SCN and related hypothalamic structures, disrupting circadian timekeeping. Additionally, pineal gland dysfunction reduces melatonin output, further compromising circadian alignment.

Pathophysiology

SCN Tau Pathology

The suprachiasmatic nucleus is particularly vulnerable to tau pathology in PSP:

| Finding | Evidence |
|---------|----------|
| SCN neuronal loss | Postmortem studies show 30-50% neuronal loss in PSP |
| Tau inclusion formation | 4R-tau inclusions documented in SCN neurons |
| Neuroinflammation | Activated microglia surrounding SCN |
| Functional disconnection | Loss of SCN output to peripheral clocks |

The SCN contains approximately 20,000 neurons that generate circadian rhythms in locomotor activity, sleep-wake cycles, hormone secretion, and body temperature. Tau-mediated SCN degeneration in PSP disrupts these coordinated rhythms[^song2019].

Pineal Gland Dysfunction

The pineal gland produces melatonin, the "hormone of darkness" that:

• Signals nighttime to peripheral tissues
• Enhances sleep quality and glymphatic clearance
• Provides antioxidant protection to neurons
• Modulates immune function

In PSP, pineal gland involvement includes:

• Reduced melatonin secretion — documented in PSP patients vs. age-matched controls[^videnovic2014]
• Calcification acceleration — age-related pineal calcification is enhanced[^lamorgia2018]
• Tau pathology in pinealocytes — occasional inclusion formation
• Disrupted melatonin rhythm — loss of normal nocturnal surge

SCN-Pineal Circuit Disconnection

A key mechanism in PSP circadian dysfunction is the disconnection between SCN and pineal gland:

Downstream Effects of Circadian Disruption

Circadian dysfunction in PSP produces cascading effects:

Sleep-wake fragmentation

• Reduced sleep efficiency
• Frequent nocturnal awakenings
• Daytime sleepiness and napping

Body temperature dysregulation

• Reduced amplitude of temperature rhythm
• Impaired nighttime dip
• Altered thermoregulatory responses

Hormonal dysregulation

• Cortisol rhythm flattening
• Growth hormone alterations
• Reduced melatonin effects on peripheral tissues

Cognitive impairment exacerbation

• SCN output to prefrontal cortex disrupted
• Executive function further compromised
• Attention and vigilance impaired

Clinical Manifestations

Sleep-Wake Pattern Abnormalities

| Feature | Prevalence in PSP | Impact |
|---------|-------------------|--------|
| Sleep onset insomnia | 40-60% | Delayed sleep onset |
| Sleep fragmentation | 60-80% | Frequent awakenings |
| Early morning awakening | 30-50% | Advanced sleep phase |
| Excessive daytime sleepiness | 40-70% | Napping during day |
| REM sleep behavior disorder | 10-20% | Sleep-enacting behaviors |

Temporal Distribution of Symptoms

Circadian dysfunction affects the temporal pattern of PSP symptoms:

• Morning worsening — motor and cognitive symptoms worse in morning hours
• Afternoon improvement — some patients show afternoon "on" periods
• Evening phenomenon — sunset can trigger symptom exacerbation
• Nocturnal agitation — sundowning-like phenomenon

Comparison with Other Movement Disorders

| Feature | PSP | PD | MSA | CBS |
|---------|-----|----|-----|-----|
| Circadian dysfunction severity | +++ | ++ | +++ | ++ |
| Melatonin reduction | +++ | ++ | ++ | + |
| SCN vulnerability | High | Moderate | High | Moderate |
| Sleep fragmentation | Severe | Moderate | Severe | Moderate |

Diagnostic Implications

Circadian Biomarkers

Circadian function assessment may aid PSP diagnosis:

| Marker | Assessment Method | Utility |
|--------|-------------------|---------|
| Dim light melatonin onset (DLMO) | Serial saliva sampling | Research |
| Core body temperature rhythm | Continuous monitoring | Research |
| Actigraphy patterns | Wearable monitoring | Clinical |
| Cortisol rhythm | Serial serum sampling | Research |
| Melatonin metabolite levels | Urine/serum 6-SMT | Emerging |

Circadian Phenotyping

PSP patients can be classified by circadian phenotype:

• Advanced sleep phase — early evening sleep, early morning awakening
• Irregular sleep-wake — no consistent pattern
• Fragmented rhythm — multiple short sleep episodes
• Relative preservation — intact circadian organization (minority)

Therapeutic Approaches

Circadian-Targeted Interventions

Light therapy

• Bright light exposure in morning
• Light avoidance in evening
• Timing critical for entrainment

Melatonin supplementation

• Evening melatonin administration
• Dose: 0.5-5 mg at bedtime
• May improve sleep and reduce sundowning[^hood2014]

Sleep hygiene optimization

• Consistent sleep-wake schedule
• Temperature control in bedroom
• Darkness maximization at night

Pharmacological approaches

• Ramelteon (melatonin agonist)
• Tasimelteon (circadian stabilizer)
• Suvorexant (orexin antagonist for sleep onset)

Lifestyle modifications

• Regular exercise timing
• Meal timing consistency
• Avoiding evening light exposure

Research Directions

Emerging Questions

• Can circadian biomarkers predict PSP progression?
• Does treating circadian dysfunction slow disease progression?
• What is the relationship between SCN pathology and cognitive decline in PSP?
• Can chronotherapy improve PSP clinical outcomes?

Clinical Trials

• Melatonin supplementation trials in PSP (ongoing)
• Light therapy feasibility studies
• Circadian rhythm assessment in clinical trial endpoints

Cross-References

Related pages in NeuroWiki:

• [Sleep and Circadian Disorders in PSP](/mechanisms/psp-sleep-circadian-disorders)
• [Glymphatic System Dysfunction in PSP](/mechanisms/psp-glymphatic-system-dysfunction)
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
• [PSP Autonomic Dysfunction](/mechanisms/psp-autonomic-dysfunction)
• [HPA Axis Dysfunction in PSP](/mechanisms/psp-hpa-axis-stress-response-dysfunction)
• [PSP Cognitive Impairment](/diseases/psp-cognitive-impairment)

References

[Welsh et al., Circadian rhythms and dementia (1985)](https://pubmed.ncbi.nlm.nih.gov/4016814/)

[Swaab & Fliers, A sexually dimorphic nucleus in the human brain (1985)](https://pubmed.ncbi.nlm.nih.gov/4097271/)

[Videnovic & Golombek, Circadian and sleep alterations in Parkinson disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29054276/)

[Hood & Amir, Clocking depression (2017)](https://pubmed.ncbi.nlm.nih.gov/29016904/)

[La Morgia et al., Melatonin and circadian rhythm in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31141647/)

[Liu et al., Circadian disruption and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33901101/)

[Cortese et al., Sleep dysfunction in atypical parkinsonism (2022)](https://pubmed.ncbi.nlm.nih.gov/33587585/)

See Also

• [Sleep and Circadian Disorders in PSP](/mechanisms/psp-sleep-circadian-disorders)
• [Glymphatic System Dysfunction in PSP](/mechanisms/psp-glymphatic-system-dysfunction)
• [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
• [PSP Autonomic Dysfunction](/mechanisms/psp-autonomic-dysfunction)
• [HPA Axis Dysfunction in PSP](/mechanisms/psp-hpa-axis-stress-response-dysfunction)
• [PSP Cognitive Impairment](/diseases/psp-cognitive-impairment)